Vascular endothelial growth factor tyrosine kinase inhibitors (VEGF-TKIs) have been the
mainstay of treatment for patients with advanced renal cell carcinoma (RCC). Despite its …

Renal cell carcinoma (RCC) is the most prevalent type of kidney cancer originating from
renal tubular epithelial cells, with clear cell RCC comprising approximately 80% of cases …

Clear cell renal carcinoma (ccRCC) is a heterogeneous disease with a variable post-
surgical course. To assemble a comprehensive ccRCC tumor microenvironment (TME) …

Immune cells in the tumor microenvironment modulate cancer progression and are attractive
therapeutic targets. Macrophages and T cells are key components of the microenvironment …

Monocytes and macrophages are major components of the tumor microenvironment, but
their contributions to human cancer are poorly understood. We used molecular profiling …

Renal cell carcinoma (RCC) refers to renal-epithelial cancer, which represents over 90% of
kidney cancer and is a cause for cancer related deaths in the world. Studies suggested …

Extensive research indicates that tumor stemness promotes tumor progression.
Nonetheless, the underlying roles of stemness-related genes in renal clear cell carcinoma …

Background Understanding the past and future burden of kidney cancer in China over years
provides essential references for optimizing the prevention and management strategies …

Renal cell carcinoma (RCC) is a tumor with unpredictable presentation and poor clinical
outcome. RCC is always resistant to chemotherapy and radiation, and weakly sensitive to …

β-Catenin (CTNNB1 gene coding protein) is a component of the Wnt signaling pathway that
has been shown to play an important role in the formation of certain cancers. Abnormal …